Genetic Signatures

Genetic Signatures Equity

The The Equity of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is 35.72 M AUD. In the previous year, The Equity was 50.09 M AUD — a change of -28.69% (lower).

Equity

35.72 MAUD

YoY

-28.69%

Last updated:

In 2026, Genetic Signatures's equity was 35.72 M AUD, a -28.69% increase from the 50.09 M AUD equity in the previous year.

The Genetic Signatures Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
10.57 M AUD
Jan 1, 2020
45.93 M AUD
Jan 1, 2021
49.34 M AUD
Jan 1, 2022
54.80 M AUD
Jan 1, 2023
42.91 M AUD
Jan 1, 2024
61.10 M AUD
Jan 1, 2025
50.09 M AUD
Jan 1, 2026
35.72 M AUD
The Genetic Signatures Equity history
YEAREquityYoY
35.72 MAUD-28.69%
50.09 MAUD-18.02%
61.10 MAUD+42.38%
42.91 MAUD-21.69%
54.80 MAUD+11.07%
49.34 MAUD+7.43%
45.93 MAUD+334.56%
10.57 MAUD-21.12%
13.40 MAUD-18.72%
16.49 MAUD+252.27%
4.68 MAUD-33.69%
7.06 MAUD-56.38%
16.18 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Genetic Signatures's Equity

Genetic Signatures's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Genetic Signatures's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Genetic Signatures's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Genetic Signatures's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Genetic Signatures’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Genetic Signatures stock

The Equity of Genetic Signatures is 35.72 M AUD in 2026.

The Equity of Genetic Signatures changed from 50.09 M AUD to 35.72 M AUD, representing a -28.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Genetic Signatures historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Genetic Signatures

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Genetic Signatures